Prognostic and predictive markers in cancer
Prognostic and predictive markers in cancer
复制标题
DOI：
10.1155/2004/202031
复制
发表时间：
2004-01-01
期刊：
影响因子：
--
通讯作者：
Taube, SE
中科院分区：
文献类型：
--
作者：
Conley, BA;Taube, SE
人类基因组的阐明以及分子异常、信号通路、局部组织环境的影响和遗传多态性的相关性方面的知识进展，为设计更有效、个性化的癌症治疗计划提供了希望。虽然科学和医学文献充满了癌症的推定预后或预测标志物的报告，但很少有新的诊断方法被纳入常规临床实践。需要标准来a）鉴定有希望在临床上有用的标志物; B）评估用于所讨论的标志物的临床评价的最佳方法和c）确认或验证与单独使用标准预后因素相比，使用标志物增加了有用的信息。这篇综述提出了一种方法，用于癌症的推定预后和预测标志物的临床评价，考虑到早期评价的陷阱，开发和优化检测方法的基本原理，以及评估推定标志物的临床效用的可能临床试验的例子。
The elucidation of the human genome and advances in knowledge about molecular abnormalities, signaling pathways, influence of the local tissue milieu and the relevance of genetic polymorphisms offer hope of designing more effective, individualized cancer treatment plans. Although the scientific and medical literature is replete with reports of putative prognostic or predictive markers for cancer, few new diagnostics have been incorporated into routine clinical practice. Criteria are needed to a) identify markers that have the promise to be clinically useful; b) assess the best methodology for clinical evaluation of the markers in question and c) confirm or validate that using the marker adds useful information compared to using standard prognostic factors alone. This review presents a methodology for the clinical evaluation of putative prognostic and predictive markers in cancer, with considerations of pitfalls in the early evaluation, rationale for development and optimization of assay methodology, and examples of possible clinical trials for assessing the clinical utility of putative markers.